Jonathan L. Halperin, M.D., F.A.C.C., F.A.H.A., F.A.C.P., M.S.V.M.
Jonathan L. Halperin is the Robert and Harriet Heilbrunn Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Associate Director of the Cardiovascular Institute at Mount Sinai Medical Center. He was the principal cardiologist responsible for the design and execution of the Stroke Prevention in Atrial Fibrillation (SPAF) clinical trials, and directed the trials that evaluated the first oral direct thrombin inhibitor oral factor Xa inhibitor drugs for this indication. He served as Chair of the ACC/AHA Task Force on Practice Guidelines, Co-Chair of the ACC Clinical Competence Committee, as a member of the FDA Cardiovascular and Renal Drugs Advisory Committee, and is Deputy Editor of The Journal of the American College of Cardiology (JACC).
